医学
下尿路症状
重症监护医学
坦索罗辛
随机对照试验
心理干预
临床试验
疾病
药物治疗
自然史
生活质量(医疗保健)
系统回顾
梅德林
内科学
增生
前列腺
护理部
癌症
精神科
政治学
法学
作者
Guglielmo Mantica,Francesca Ambrosini,Giovanni Drocchi,Zlata Zubko,Lorenzo Lo Monaco,Angelo Cafarelli,Alessandro Calarco,Renzo Colombo,Ottavio De Cobelli,Ferdinando De Marco,Giovanni Ferrari,Giuseppe Mario Ludovico,Stefano Pecoraro,Domenico Tuzzolo,Carlo Terrone,Rosario Leonardi
标识
DOI:10.4081/aiua.2024.13098
摘要
Benign prostatic hyperplasia (BPH) is a common urological disease that is strongly associated with the aging process and can lead to lower urinary tract symptoms (LUTS). LUTS due to BPH can significantly affect the quality of life of many patients. Among the treatments available for BPH to improve symptoms and functional outcomes, drug therapy and surgical therapy are the options of choice. However, for most patients with symptomatic BPH, medical management remains the cornerstone of treatment. Pharmacologic interventions are often preferred as a first approach, being less invasive compared to surgery. Although the medical treatment of BPH is currently defined by the algorithms of international guidelines, the need for a more personalized approach is increasingly recognized given the wide and heterogeneous range of therapeutic options available.
科研通智能强力驱动
Strongly Powered by AbleSci AI